Phase 3 Readout
ADCT: Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera
June 30, 2028 · loncastuximab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2028
- Company
- ADC Therapeutics SA (ADCT)
- Drug
- loncastuximab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera
- Company
- ADC Therapeutics SA (ADCT)
- Drug
- loncastuximab
- Indication
- Refractory Diffuse Large B-Cell Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma